Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$0.36 -7.8%	$0.35	$0.22 ▼ $15.80	$17.78M	0.79	826,444 shs	298,778 shs
CMMB Chemomab Therapeutics	$0.93 +3.6%	$1.12	$0.87 ▼ $2.55	$17.54M	0.52	126,395 shs	124,827 shs
CPHI China Pharma	$1.43 -2.1%	$1.70	$1.20 ▼ $3.35	$4.67M	0.87	110,402 shs	23,074 shs
PASG Passage Bio	$6.95 -8.4%	$7.07	$5.12 ▼ $26.60	$22.09M	1.81	82,426 shs	61,740 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	0.00%	+6.85%	+0.84%	+35,899,900.00%	+35,899,900.00%
CMMB Chemomab Therapeutics	0.00%	-4.11%	-17.70%	-32.12%	-11.43%
CPHI China Pharma	0.00%	-3.70%	-21.47%	-35.59%	-92.12%
PASG Passage Bio	0.00%	+10.85%	+20.45%	+15.07%	-53.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	3.4475 of 5 stars	3.5	5.0	0.0	0.0	3.1	1.7	0.6
CPHI China Pharma	0.7811 of 5 stars	0.0	5.0	0.0	0.0	1.9	0.8	0.0
PASG Passage Bio	3.7821 of 5 stars	3.5	5.0	0.0	0.0	2.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASBP Aspire Biopharma	0.00	N/A	N/A	N/A
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	813.98% Upside
CPHI China Pharma	0.00	N/A	N/A	N/A
PASG Passage Bio	3.00	Buy	$91.75	1,220.14% Upside

Current Analyst Ratings Breakdown

Latest CPHI, PASG, ASBP, and CMMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	PASG Passage Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$260.00 ➝ $67.00
8/13/2025	PASG Passage Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	($2.17) per share	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
CPHI China Pharma	$4.30M	1.09	N/A	N/A	$0.70 per share	2.04
PASG Passage Bio	N/A	N/A	N/A	N/A	$19.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASBP Aspire Biopharma	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	-737.96%	N/A
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-88.15%	-70.00%	8/20/2025 (Estimated)
CPHI China Pharma	-$3.08M	N/A	0.00	∞	N/A	-85.56%	-63.93%	-31.42%	N/A
PASG Passage Bio	-$64.77M	-$18.16	N/A	N/A	N/A	N/A	-103.87%	-59.95%	N/A

Latest CPHI, PASG, ASBP, and CMMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/13/2025	Q2 2025	ASBP Aspire Biopharma	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/12/2025	Q2 2025	PASG Passage Bio	-$4.00	-$2.96	+$1.04	-$2.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASBP Aspire Biopharma	N/A	0.09	0.09
CMMB Chemomab Therapeutics	N/A	5.33	5.33
CPHI China Pharma	0.22	0.79	0.26
PASG Passage Bio	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASBP Aspire Biopharma	19.17%
CMMB Chemomab Therapeutics	46.05%
CPHI China Pharma	N/A
PASG Passage Bio	53.48%

Insider Ownership

Company	Insider Ownership
ASBP Aspire Biopharma	48.00%
CMMB Chemomab Therapeutics	11.91%
CPHI China Pharma	17.32%
PASG Passage Bio	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASBP Aspire Biopharma	N/A	49.53 million	25.75 million	N/A
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
CPHI China Pharma	250	3.26 million	15.92 million	Not Optionable
PASG Passage Bio	130	3.18 million	3.04 million	Optionable

CPHI, PASG, ASBP, and CMMB Headlines

Recent News About These Companies

Wedbush Comments on Passage Bio's Q3 Earnings (NASDAQ:PASG)

August 16 at 2:43 AM | americanbankingnews.com

Passage Bio (PASG) Receives a Buy from TD Cowen

August 15 at 9:03 PM | theglobeandmail.com

Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade

August 15 at 10:55 AM | zacks.com

Canaccord Genuity Group Lowers Passage Bio (NASDAQ:PASG) Price Target to $67.00

August 15 at 4:03 AM | americanbankingnews.com

Wedbush Issues Positive Forecast for Passage Bio (NASDAQ:PASG) Stock Price

August 15 at 3:09 AM | americanbankingnews.com

Passage Bio price target lowered to $67 from $260 at Canaccord

August 14 at 11:34 PM | msn.com

Passage Bio Reports Q2 2025 Progress and Financials

August 13, 2025 | msn.com

Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year

August 12, 2025 | msn.com

Passage Bio Reports Promising Q2 2025 Financial Results

August 12, 2025 | msn.com

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

August 12, 2025 | globenewswire.com

Passage Bio (PASG) Projected to Post Quarterly Earnings on Thursday

August 7, 2025 | americanbankingnews.com

Passage Bio Regains Nasdaq Compliance with Stock Price

July 29, 2025 | tipranks.com

Insider Buying: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Acquires 13,123 Shares of Stock

July 25, 2025 | insidertrades.com

Passage Bio Announces 1-for-20 Reverse Stock Split

July 10, 2025 | globenewswire.com

Passage Bio, Inc. (PASG) Income Statement - Yahoo Finance

July 1, 2025 | finance.yahoo.com

PASG Passage Bio, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 Shares

June 27, 2025 | insidertrades.com

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

June 23, 2025 | globenewswire.com

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development

May 17, 2025 | msn.com

Passage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestre

May 13, 2025 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI, PASG, ASBP, and CMMB Company Descriptions

Aspire Biopharma NASDAQ:ASBP

$0.36 -0.03 (-7.83%)

As of 08/15/2025 04:00 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Chemomab Therapeutics NASDAQ:CMMB

$0.93 +0.03 (+3.64%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.95 +0.02 (+2.15%)

As of 08/15/2025 07:59 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

China Pharma NYSE:CPHI

$1.43 -0.03 (-2.05%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$1.40 -0.02 (-1.75%)

As of 08/15/2025 07:58 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Passage Bio NASDAQ:PASG

$6.95 -0.64 (-8.43%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$7.00 +0.04 (+0.65%)

As of 08/15/2025 07:53 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time